July 14, 2020

INDIA: Biocon’s Itolizumab approved for COVID-19 treatment: All you need to know. “The company has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. Biocon says Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with such complications.”

InstaPundit is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.